AU2018218310B2 - Rescue treatment of post operative nausea and vomiting - Google Patents

Rescue treatment of post operative nausea and vomiting Download PDF

Info

Publication number
AU2018218310B2
AU2018218310B2 AU2018218310A AU2018218310A AU2018218310B2 AU 2018218310 B2 AU2018218310 B2 AU 2018218310B2 AU 2018218310 A AU2018218310 A AU 2018218310A AU 2018218310 A AU2018218310 A AU 2018218310A AU 2018218310 B2 AU2018218310 B2 AU 2018218310B2
Authority
AU
Australia
Prior art keywords
amisulpride
antagonist
ponv
emetic
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018218310A
Other languages
English (en)
Other versions
AU2018218310A1 (en
Inventor
Gabriel Fox
Julian Clive Gilbert
Robert William Gristwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acacia Pharma Ltd
Original Assignee
Acacia Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acacia Pharma Ltd filed Critical Acacia Pharma Ltd
Publication of AU2018218310A1 publication Critical patent/AU2018218310A1/en
Application granted granted Critical
Publication of AU2018218310B2 publication Critical patent/AU2018218310B2/en
Priority to AU2024203155A priority Critical patent/AU2024203155B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018218310A 2017-02-10 2018-02-09 Rescue treatment of post operative nausea and vomiting Active AU2018218310B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024203155A AU2024203155B2 (en) 2017-02-10 2024-05-13 Rescue treatment of post operative nausea and vomiting

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1702250.0A GB201702250D0 (en) 2017-02-10 2017-02-10 Method
GB1702250.0 2017-02-10
PCT/GB2018/050374 WO2018146490A1 (en) 2017-02-10 2018-02-09 Rescue treatment of post operative nausea and vomiting

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024203155A Division AU2024203155B2 (en) 2017-02-10 2024-05-13 Rescue treatment of post operative nausea and vomiting

Publications (2)

Publication Number Publication Date
AU2018218310A1 AU2018218310A1 (en) 2019-08-22
AU2018218310B2 true AU2018218310B2 (en) 2024-02-15

Family

ID=58462198

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018218310A Active AU2018218310B2 (en) 2017-02-10 2018-02-09 Rescue treatment of post operative nausea and vomiting
AU2024203155A Active AU2024203155B2 (en) 2017-02-10 2024-05-13 Rescue treatment of post operative nausea and vomiting

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024203155A Active AU2024203155B2 (en) 2017-02-10 2024-05-13 Rescue treatment of post operative nausea and vomiting

Country Status (14)

Country Link
US (4) US11357753B2 (enExample)
EP (1) EP3579831A1 (enExample)
JP (2) JP7333269B2 (enExample)
KR (2) KR20190111993A (enExample)
CN (1) CN110603036A (enExample)
AU (2) AU2018218310B2 (enExample)
BR (1) BR112019016565A2 (enExample)
CA (1) CA3052535A1 (enExample)
EA (1) EA201991667A1 (enExample)
GB (1) GB201702250D0 (enExample)
IL (2) IL298486B2 (enExample)
MX (1) MX388736B (enExample)
WO (1) WO2018146490A1 (enExample)
ZA (1) ZA201905212B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201702250D0 (en) * 2017-02-10 2017-03-29 Acacia Pharma Ltd Method
IT201900013524A1 (it) * 2019-07-31 2021-01-31 Laboratori Baldacci Spa Nuove formulazioni di amisulpride
WO2022008901A1 (en) * 2020-07-06 2022-01-13 Acacia Pharma Ltd Therapy of post-operative nausea and vomiting

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011110854A2 (en) * 2010-03-11 2011-09-15 Acacia Pharma Limited The use of amisulpride as an anti-emetic
WO2016162695A1 (en) * 2015-04-10 2016-10-13 Acacia Pharma Limited Combinations of amisulpride and another anti-emetic for treating nausea and vomiting

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1004020A (en) 1964-04-24 1965-09-08 Standard Telephones Cables Ltd Improvements in or relating to the mounting of electrical components
FR2415099A1 (fr) 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
GB9305593D0 (en) 1993-03-18 1993-05-05 Smithkline Beecham Plc Pharmaceuticals
US6169094B1 (en) 1998-07-14 2001-01-02 Sanofi-Synthelabo Compositions of (S) (-)-amisulpride
DE10163421A1 (de) 2001-12-21 2003-07-31 Gruenenthal Gmbh Verwendung von (+)-(1S,2S)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol als Antiemetikum
MY143789A (en) 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
DE102005013726A1 (de) 2005-03-22 2006-09-28 Grünenthal GmbH Transdermale therapeutische Systeme mit verbesserter Verträglichkeit
GB0506800D0 (en) 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
WO2007067714A2 (en) 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
AU2007211091B8 (en) 2006-01-27 2013-08-29 Adare Pharmaceuticals, Inc. Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids
EP1988883A1 (fr) 2006-02-17 2008-11-12 Trimaran Limited Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
US7825156B2 (en) 2007-02-02 2010-11-02 Copharms Method of treating bipolar depression with a benzamide derivative
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
US8138169B2 (en) 2008-04-11 2012-03-20 Comgenrx, Inc. Combination therapy for bipolar disorder
US20110003005A1 (en) 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
RS53491B1 (sr) 2009-11-18 2015-02-27 Helsinn Healthcare Sa Kompozicije za lečenje centralno posredovane mučnine i povraćanja
MX353209B (es) 2010-06-18 2018-01-08 Altos Therapeutics Llc Antagonistas d2, metodos de sintesis y metodos de uso.
WO2015054429A1 (en) 2013-10-08 2015-04-16 Innopharma, Inc Aprepitant oral liquid formulations
GB201618425D0 (en) 2016-11-01 2016-12-14 Acacia Pharma Ltd method
GB201702250D0 (en) * 2017-02-10 2017-03-29 Acacia Pharma Ltd Method

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011110854A2 (en) * 2010-03-11 2011-09-15 Acacia Pharma Limited The use of amisulpride as an anti-emetic
WO2016162695A1 (en) * 2015-04-10 2016-10-13 Acacia Pharma Limited Combinations of amisulpride and another anti-emetic for treating nausea and vomiting

Also Published As

Publication number Publication date
US20200038369A1 (en) 2020-02-06
US20250367211A1 (en) 2025-12-04
EA201991667A1 (ru) 2020-02-11
US20240285579A1 (en) 2024-08-29
IL268591B (en) 2022-12-01
IL298486A (en) 2023-01-01
ZA201905212B (en) 2023-12-20
MX388736B (es) 2025-03-20
US20230100786A1 (en) 2023-03-30
JP2020506209A (ja) 2020-02-27
AU2024203155B2 (en) 2025-03-13
CN110603036A (zh) 2019-12-20
IL268591B2 (en) 2023-04-01
IL298486B1 (en) 2024-05-01
IL298486B2 (en) 2024-09-01
AU2018218310A1 (en) 2019-08-22
NZ756051A (en) 2024-04-26
US11357753B2 (en) 2022-06-14
CA3052535A1 (en) 2018-08-16
US12005042B2 (en) 2024-06-11
KR20190111993A (ko) 2019-10-02
EP3579831A1 (en) 2019-12-18
KR20240001288A (ko) 2024-01-03
WO2018146490A1 (en) 2018-08-16
BR112019016565A2 (pt) 2020-03-31
JP2023027213A (ja) 2023-03-01
AU2024203155A1 (en) 2024-05-30
IL268591A (en) 2019-09-26
JP7526244B2 (ja) 2024-07-31
GB201702250D0 (en) 2017-03-29
US12329740B2 (en) 2025-06-17
JP7333269B2 (ja) 2023-08-24

Similar Documents

Publication Publication Date Title
AU2024203155B2 (en) Rescue treatment of post operative nausea and vomiting
US20240050403A1 (en) Therapy of post-operative emesis with amisulpride
US20230263770A1 (en) Therapy of post-operative nausea and vomiting
JPWO2018146490A5 (enExample)
NZ796242A (en) Rescue treatment of post operative nausea and vomiting
EA042759B1 (ru) Экстренное лечение постоперационной тошноты и рвоты
HK40013552A (en) Rescue treatment of post operative nausea and vomiting
NZ792875A (en) Therapy of post-operative emesis with amisulpride
EA044539B1 (ru) Терапия постоперационной рвоты амисульпридом

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)